Healthcare acquired infections (HAIs) are the most common complication of hospital care. A recent survey funded by CareFusion and conducted by ONS:Edge aimed at evaluating infection prevention knowledge and practices among oncology nurses. Download a free copy of the knowledge report which offers a summary of the survey results, along with additional information and resources about infection prevention for oncology nurses.
A New ONS:Edge White Paper: Managing Skin Toxicities from Chemotherapy, Targeted Therapy & Radiation
At the 2014 ONS Annual Congress, Lindi Skin, in partnership with ONS:Edge, Inc., distributed a new White Paper “Managing Skin Toxicities with Lindi Skin Products”, along with samples of their products. The White Paper briefly summarizes the types of skin effects that oncology nurses are likely to see in their patients, such as radiation dermatitis, the impacts of traditional chemotherapy, and the rashes and hand foot syndrome caused by some targeted anti-cancer agents.
Click here for more information and to download a copy of the white paper
A recent ONS:Edge survey explored what oncology nurses do for their patients to manage chemotherapy-induced nausea and vomiting (CINV). To help oncology nurses learn about one treatment option, SANCUSO® (Granisetron Transdermal System), ONS:Edge and ProStrakan developed a white paper that reports on the survey results, the use of Sancuso, clinical practice guidelines, instructions on how to use the patch, and patient-support programs.
©2013 ProStrakan Inc.
All rights reserved. SAN-046 November 2013
Review current practice in managing advanced NSCLC. VeriStrat® is a serum protein test for patients with advanced non-small cell lung cancer (NSCLC) that helps healthcare providers select therapy when considering erlotinib (Tarceva®, Genentech) or single-agent chemotherapy.
Click here for more information and to request additional printed copies of the ONS:Edge white paper titled “Advancing Personalized Therapy for Advanced Non-Small Cell Lung Cancer.”